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The development of a fluorescent anti-factor Xa (FXa) assay and its application to the 
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Abstract 
Fluorogenic assays have many potential advantages over traditional clot-based and 
chromogenic assays such as the absence of interference from a range of factor deficiencies as 
well as offering the possibility of assays in platelet rich plasma or whole blood. A fluorogenic 
anti-factor Xa (anti-FXa) assay has been developed for the determination of heparin-like 
anticoagulants including unfractionated heparin (UFH), low-molecular weight heparins 
(LMWHs), namely enoxaparin and tinzaparin, and the synthetic heparinoid danaparoid, in 
commercial human pooled plasma. The assay was based on the complexation of heparin-
spiked plasmas with exogenous FXa at a concentration of 4 nM in the presence of 0.9 µM of 
the fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4-
methylcoumarin acetate (Pefafluor FXa). Pooled plasma samples were spiked with 
concentrations of anticoagulants in the range 0 to 1.6 U/ml. The assay was capable of the 
measurement of UFH and danaparoid in the range 0-1 U/ml, and enoxaparin and tinzaparin in 
the range 0-0.8 U/ml and 0-0.6 U/ml, respectively. Assay percentage coefficients of variation 




Antithrombotic drugs are routinely used for a wide range of clinical indications, 
including the prevention and treatment of venous thromboembolism (VTE) and the acute 
management of ischaemic heart disease [1, 2]. Unfractionated heparin (UFH) constitutes the 
most widely used parenteral antithrombotic therapy [3, 4], and consists of a heterogeneous 
mixture of negatively-charged glycosaminoglycans derived from either bovine lung, or 
porcine intestine. UFH exerts its anticoagulant effect primarily through binding to plasma 
antithrombin (AT) [5]. This binding causes a conformational change in antithrombin, which 
markedly enhances the ability of antithrombin to specifically inhibit procoagulant factors Xa 
(FXa) and thrombin (IIa) [1].  
Low molecular weight heparins (LMWHs) are synthesised by chemical or enzymatic 
depolymerisation of heterogeneous UFH glycosaminoglycan chains [1, 6]. LMWHs 
demonstrate better bioavailability, have significantly longer half-lives compared to UFH [1], 
and are also associated with reduced incidence of significant complications [7]. 
Consequently, UFH has been replaced by LMWH as the treatment of choice for many 
indications. Although the LMWHs share many pharmacodynamic properties, commercial 
products differ significantly with respect to final molecular weights (4000-7000 Da) [4]. 
Although the LMWHs all bind to AT, they demonstrate different abilities to enhance 
inactivation of FXa and/or thrombin (anti-FXa:anti-FIIa ratios ranging from 2:1 to 4:1) [8]. 
Danaparoid is prepared from bovine and porcine mucosa, and is classed as a low molecular 
weight heparinoid which has an anti-FXa:anti-IIa ratio of ≥22:1 [9].  
Despite its widespread use, it is well recognized that UFH has a relatively narrow 
therapeutic window [1]. Consequently, laboratory monitoring and dose-titration of UFH 
therapy is standard clinical practice. In contrast, because of more predictable pharmacokinetic 
profiles, LMWH therapy typically requires less laboratory monitoring. A number of different 
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laboratory assays have been used to enable adjustment of heparin doses. Most commonly 
used are clot-based assays in the form of the activated partial thromboplastin time (APTT) 
[10] and the activated clotting time (ACT) [11]. Nevertheless, it is well established that these 
assays have a number of important limitations. First, since the APTT is a standard end-point 
clotting time assay, it can be influenced by many other coagulation variables. For example, 
the APTT will be prolonged by inherited or acquired coagulation factor deficiencies 
(including factors XII, XI, X, IX, VIII, V, and II) [8, 12]. Second, more than 300 different 
laboratory tests are in clinical use to measure the APTT. Previous reports have clearly shown 
that varying combinations of different commercial reagents and coagulometer machines can 
result in marked inter-laboratory variability in responsiveness to therapeutic UFH 
concentrations [13, 14]. Similarly, although the ACT is widely used to monitor heparin 
reversal in patients during cardiac surgery, it is also associated with important limitations 
[15]. 
Since the APTT is generally insensitive to LMWH, plasma anti-FXa activity 
monitoring is established as the assay of choice for those patients who require monitoring. In 
addition, the anti-FXa assay can also be used to monitor UFH levels. Moreover, since the 
anti-FXa assay generally involves a chromogenic end-point, use of this assay to monitor UFH 
levels is attractive in that it is not affected by many of the other biologic variable that can 
interfere with clot-based end-points. While chromogenic assays confer many advantages over 
standard clot-based assays, there are some drawbacks. The use of chromogenic substrates 
requires measuring optical density, which renders whole blood and platelet rich plasma 
samples problematic for colorimetric measurements [16]. Fibrinogen clotting results in 
turbidity of plasma samples which interferes negatively with absorbance readings [16-18]. 
Also the lack of a standard anti-FXa chromogenic assay gives rise to significant inter-
variability between commercially available assays [13, 19].   
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The potential advantages of fluorogenic assays over chromogenic assays include the 
ability to use a range of sample types such as platelet poor (PPP), platelet rich (PRP) and 
whole blood samples, as fluorescence is not as influenced by the opacity of the sample as 
absorbance [18]. Although fluorogenic assays to assess thrombin generation have been 
developed, there is accumulating evidence that FXa may represent a better target as it 
occupies a critical junction in the coagulation cascade [20]. In this study, we have sought to 
develop a novel plate-based fluorogenic anti-FXa assay that is sensitive to pharmacological 
concentrations of UFH, LMWHs, and danaparoid.  
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2. Materials and methods 
2.1. Reagents 
Water (ACS reagent), HEPES (minimum 99.5% titration) and sodium citrate tribasic 
dehydrate (ACS reagent, 99.0%) were all from Sigma-Aldrich (Ireland). Filtered HEPES and 
sodium citrate solutions had concentrations of 10 mM (pH 7.4) and 0.1 M (pH 5.5), 
respectively. A 100 mM filtered stock solution of CaCl2 was prepared from a 1 M CaCl2 
solution (Fluka BioChemika, Switzerland). The fluorogenic substrate methylsulfonyl-D-
cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor FXa) was 
purchased from Pentapharm (Basel, Switzerland). It was reconstituted in 1 ml of water 
having a final concentration of 10 mM, aliquoted and stored at -20°C until further use. 
Dilutions from 10 mM stock solutions down to 10 µM were freshly prepared with water 
when needed. Subsequent dilutions were prepared in 10 mM HEPES. Tubes were covered 
with aluminum foil to protect from exposure to light. Purified human Factor Xa (FXa) was 
obtained from HYPHEN BioMed (Neuville-Sur-Oise, France). Tinzaparin (Innohep®) was 
obtained from LEO Pharma (Ballerup, Denmark). UFH, enoxaparin (Clexane®) and 
danaparoid (Orgaran®) were from Sigma-Aldrich (St Louis, MO), Sanofi-Aventis (Paris, 
France) and Schering-Plough (Kenilworth, NJ), respectively. Human pooled plasma was 
purchased from Helena Biosciences Europe (Tyne and Wear, UK). Lyophilised plasma was 
reconstituted in 1 ml of water and left to stabilize for at least 20 min at room temperature 
prior to use.  
2.2. Apparatus and software 
Fluorescence intensities were measured in a microplate reader (Spectrophotometer Infinite 
M200, Tecan Group Ltd., Switzerland) equipped with a UV Xenon flashlamp.  Flat, black-
bottom 96-well polystyrol microplates (Nunc™ FluoroNunc™ Microplates, Roskilde, 
Denmark) were used.  
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2.3. Fluorogenic anti-FXa assay 
Measurements were carried out in reconstituted citrated human pooled plasma without 
the addition of exogenous AT. FXa and Pefafluor FXa were titrated within the range of 0.1-
10 nM and 0.1-100 µM (Km = 220 µM), respectively. Each well contained 6.25 µl of 100 mM 
CaCl2, 43.75 µl of pooled plasma, and 50 µl of FXa (0.1-10 nM). The reaction was started by 
adding 50 µl of Pefafluor FXa fluorogenic substrate (0.1-100 µM). Samples within wells 
were mixed with the aid of orbital shaking at 37°C for 30 s. Immediately after shaking, 
fluorescence measurements were recorded at 37°C for 60 min, at 20 µs intervals.  
Fluorescence excitation was at 342 nm and emission was monitored at 440 nm, 
corresponding to the excitation/emission wavelengths of the 7-amino-4-methylcoumarin 
(AMC) fluorophore. All the measurements were carried out in triplicate. Following 
optimization of assay conditions, pooled commercial plasma samples were spiked with 
pharmacologically relevant concentrations (0–1.6 U/ml) of therapeutic anticoagulants 
including UFH, enoxaparin, tinzaparin and danaparoid. In all experiments, reaction progress 
curves were obtained and analyzed in SigmaPlot 8.0. The reaction rate, which is defined as 
the change in fluorescence divided by the change in time (i.e., dF/dt), was measured as the 
linear portion of the fluorescence response profile and plotted versus all different 
anticoagulant concentrations.  
2.4. Statistical Analysis 
Inter- and intra-assay differences between anticoagulant concentrations were compared using 
one-way analysis of variance (ANOVA), with subsequent post-hoc analysis performed 
(Scheffe test) if significance was observed. A result of (p<0.05) was considered statistically 
significant. The statistical package SPSS 15.0 was used for data processing and analysis. 
 8 
3. Results  
3.1. Assay optimization  
In standard anti-FXa assays, excess FXa added to heparinized plasma is inhibited by 
the heparin-AT complex, and residual FXa activity is assessed using a chromogenic substrate 
[19, 21]. Our assay measures the rate of AMC fluorophore released by FXa substrate 
cleavage, which is inversely dependent upon plasma heparin(oid) concentration. To establish 
optimal assay concentrations, Pefafluor FXa fluorogenic substrate and FXa were titrated over 
a range of concentrations. Pefafluor FXa substrate concentration was evaluated within the 
range of 0.1 µM (0.45 x 10
-3
 times Km) to 100 µM (0.45 times Km) with FXa in excess of 
physiological concentrations (150 pM) [22] at a concentration of 1 nM.  Pefafluor FXa 
concentrations were chosen on the basis of working below and around the Km value to allow 
differentiation in reaction rates at different anticoagulant concentrations, as the difference in 
reaction rates at substrate concentrations larger than the Km is almost negligible. An example 
of the fluorogenic assay FXa/substrate titration (0.8 µM substrate and 0.1, 1 and 10 nM FXa 
concentrations) can be seen in Fig. 1. The optimized assay is capable of differentiating the 
concentration of UFH in commercial human pooled plasma from 0 to 1 U/ml, at a final assay 
concentration of 4 nM FXa and 0.9 µM Pefafluor FXa. 
(Figure 1) 
3.2. Evaluation of the anti-FXa fluorogenic assay for the quantitative determination of 
anticoagulant dose-response and assay variability 
Four heparin drugs were tested using the optimized fluorogenic anti-FXa assay in 
commercial human pooled plasma. The reaction progress curves were similar for all four 
drugs in that, as anticoagulant concentration increased, lag times were extended and reaction 
rates were reduced. This is illustrated in Fig. 2 (inset) which shows the fluorescence profiles 
of the anti-FXa assay response to UFH. For each type of anticoagulant, the reaction curves 
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reached a plateau at approximately the same level (48,000-53,000 AU) independent of 
anticoagulant concentration. This upper response limit was dictated by the substrate (and thus 
product) concentration and the upper detection limit of the instrument.  
(Figure 2) 
The dose-response profile for the assay in UFH was calculated using the linear 
regions of the fluorescence responses. It can be observed that the assay was capable of the 
differentiation of UFH concentrations from 0.2 to 1.6 U/ml at intervals of 0.2 U/ml. The 
overall response profile was non-linear. It has previously been reported that non-linearity is 
observed with wide-ranging concentrations of heparin [23] and that the half-life and intensity 
of the effects of heparin rise disproportionately with increasing heparin dose [4]. Highest 
assay sensitivity can be observed at lower heparin concentrations (0-0.6 U/ml) but at the 
upper range (0.6-1.6 U/ml) the sensitivity of the assay decreased significantly. Response 
slopes to UFH concentrations at 0.2 U/ml intervals were statistically different from one 
another (p<0.001) up to 1 U/ml UFH except for UFH concentrations of 0.6 U/ml and 0.8 
U/ml between which there was no statistical difference (p=0.441).  
The anti-FXa assay was tested further on a range of anticoagulant drugs, namely 
tinzaparin, enoxaparin and danaparoid. The fluorescence response profiles of the fluorogenic 
anti-FXa assay to tinzaparin and the associated dose-response curve can be seen in Fig. 3. 
Typically, the responses reached a plateau of around 50,000 – 55,000 AU and lag times 
increased while the slopes of the linear response region decreased with increasing 
concentration. In nearly all instances there were statistically significant differences between 
the slopes of the adjacent drug concentrations (p<0.001). The resulting dose-response curve 
was non-linear, with higher sensitivity in the lower tinzaparin range (0.2-0.6 U/ml). At higher 
concentrations of the anticoagulant, assay sensitivity again decreased, which was similar to 
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that observed for UFH. However, the highest dose tested (1.6 U/ml) could still be 
distinguished from the next concentration of 1.4 U/ml (p<0.001). LMWHs have been 
reported as giving a more predictable dose-response than UFH due to better bioavailability at 
low doses. 
(Figure 3) 
The effect of enoxaparin was also evaluated using the fluorogenic anti-FXa assay 
(Fig. 4). Fluorescence response curves showed comparable characteristics to UFH and 
tinzaparin and again reached a plateau around 50,000 AU. However, the dose-response curve 
shows that, although the anti-FXa assay had good sensitivity to enoxaparin between 0 and 0.4 
U/ml and retained moderate sensitivity up to 0.8 U/ml, at concentrations greater than 1.0 
U/ml the assay showed a significant loss in sensitivity (p>0.05). 
(Figure 4) 
Fig. 5 shows the fluorescence responses from the anti-FXa assay in the presence of 
danaparoid. Again, similar to earlier results, the fluorescence responses reached a plateau 
between 45,000-50,000 AU.   However, the lag times were more prolonged in the presence of 
danaparoid than in the presence of UFH. For example, at 0.8 U/ml danaparoid, the lag time 
ended at 2000 s compared to UFH which ended at 500 s. The slopes in the presence of 
danaparoid were also much lower than for UFH. This is likely due to the more complete 
inhibition of FXa by danaparoid as a result of its high anti-FXa:anti-FIIa activity ratio of 
≥22:1 [9]. At 1.2 U/ml the reproducibility also became a significant issue with a %CV of 
21%. Above this, it was not possible to calculate meaningful slopes. This assay was found to 
be statistically sensitive to danaparoid up to concentrations of 1 U/ml (p<0.001). 
(Figure 5) 
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Although there was a significant difference between activity at 0 and 0.2 U/ml, there 
was a near linear response of anti-FXa activity with danaparoid at concentrations of 0.2-1 
U/ml (R
2
=0.9891) which was not seen with UFH, tinzaparin or enoxaparin indicating a more 
predictable dose-response relationship. While danaparoid has little effect on standard clotting 
tests [4] it can be monitored with the anti-FXa fluorogenic assay developed in this study quite 
reliably. 
Also critical to assay performance is the relative standard deviation or percentage 
coefficient of variation (%CV). Table 1 summarizes the analytical errors associated with each 
of the slope measurements, namely the standard deviation and the percentage coefficient of 
variation for each anticoagulant drug in the anti-FXa assay. CV values for all drugs tested 
were <7% for the plate-based assay (except for a single point at 1.2 U/ml danaparoid) which 
are in line with commercially available assays [24, 25] and the WHO Expert Committee on 
Biological Standardization reports.  
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Table 1.  




UFH Tinzaparin Enoxaparin Danaparoid 
 SD %CV SD %CV SD %CV SD %CV 
0 7.29 6.26 5.03 3.16 1.94 1.73 1.3 0.96 
0.2 1.29 1.23 1.43 1.75 1.03 1.52 2.55 4.56 
0.4 2.42 3.36 2.68 4.00 0.30 0.73 1.64 3.35 
0.6 0.17 0.33 1.70 4.13 0.56 0.50 2.34 6.27 
0.8 2.13 4.61 2.48 6.55 1.62 5.28 1.02 4.13 
1.0 1.87 4.54 0.42 1.39 10.5 3.83 0.54 3.01 
1.2 0.42 1.4 1.40 5.25 0.57 2.12 4.27 20.95 
1.4 1.25 4.59 0.71 5.14 0.18 0.74 - - 
1.6 0.83 4.19 0.44 4.13 1.11 5.52 - - 
 
3.3. Comparison of responses of the anti-FXa assay to different drugs 
The inter-assay variability between drugs was also assessed. While the general trend 
for each drug was similar (Fig. 6), specific differences were observed in the response of each 
drug. An indication of the inter-assay variation is given by the results for the 0 U/ml 
measurements for the four assays. As can be seen in Fig. 6, this value varied from approx. 
115 AU/s to 160 AU/s. This variation could be due to variations in antithrombin activity 
levels in the control plasma, variations in exogenous Xa activity levels, or other experimental 
variables such as time and temperature. As a result, the inter-assay variability was 16%.  
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(Figure 6) 
Statistical analysis of the raw data indicated that concentrations of 0.2, 0.4, and 0.8 
U/ml, for all four drugs tested were significantly different from one another (p<0.001) with 
the exception of tinzaparin and UFH at 0.4 U/ml (p=0.78). At 0.6 U/ml and 1 U/ml the 
Levene’s test was p=0.020 and p=0.032, respectively. Hence, there were significant 
differences in the variances and therefore one-way ANOVA could not be applied. At 
concentrations of 1.2, 1.4, and 1.6 U/ml, statistical analysis showed significant differences 
between UFH, enoxaparin, and tinzaparin. Danaparoid data was not recorded within this 
range. 
To eliminate differences due to inter-assay variation, ratios of the dose-responses 
were made against those at 0 U/ml heparin. Statistical analysis of this normalized data 
showed specific differences from the raw data. UFH was seen to be distinctive from the 
LMWHs and danaparoid where it showed comparatively less decrease in assay activity for 
comparable doses, particularly at lower concentrations. Concentrations of 0.2, 0.8, 1, 1.4 and 
1.6 U/ml for all four drugs tested were significantly different (p<0.001). However at 0.8 
U/ml, tinzaparin and enoxaparin were not significantly different (p=0.069). Also, UFH and 
enoxaparin were not significantly different at 1.4 U/ml (p=0.064) and 1.6 U/ml (p=0.433). At 
concentrations of 0.4 U/ml (p=0.043), 0.6 U/ml (p=0.011) and 1.2 U/ml (p=0.004) significant 
differences were identified in the variances, so one-way ANOVA could not be applied. 
The responses of all four drugs to the anti-FXa fluorogenic assay can be further 
compared using the reaction rates (slopes) of the normalized data. UFH at 0.2, 0.4, 0.8, 1.2, 
1.4 and 1.6 U/ml returned higher reaction rates than both LMWHs and danaparoid. 
Enoxaparin reaction rates were higher than tinzaparin reaction rates at 0.2, 0.8, 1.4 and 1.6 
U/ml but at all other concentrations the reaction rates were the same. Danaparoid returned the 
lowest reaction rates. This pattern could relate to the molecular weights of each drug with 
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UFH at 11,393 Da, tinzaparin at 5,866 Da and enoxaparin at 4,371 Da and danaparoid at a 
similar molecular weight to LMWHs. At higher molecular weights, greater reaction rates 
were calculated indicating greater sensitivity of the assay to that particular drug. In addition a 
trend can be observed between reaction rates and anti-FXa:anti-IIa ratios which also 
correlates with the pattern observed with molecular weight, e.g. 
UFH>tinzaparin>enoxaparin>danaparoid : 1:1>1.9:1>2.7:1≥22:1. A high anti-FXa:anti-FIIa 
ratio and low molecular weight translates into a lower reaction rate value. 
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4. Discussion 
Injectable drugs such as UFH, LMWHs and associated synthetic heparinoids are 
widely used and extremely efficacious anticoagulant treatments. However, UFH needs 
careful monitoring as it suffers significantly from a narrow therapeutic window and the 
subsequent harmful implications of clotting or bleeding. As already discussed, monitoring of 
UFH has long relied on clot-based assays (APTT and ACT) which have significant 
limitations. Furthermore, although LMWHs require less laboratory monitoring due to their 
predictable pharmacokinetics, monitoring is recommended in populations where 
pharmacokinetic parameters are altered, including obesity, renal insufficiency, pregnancy, in 
underweight patients, elderly patients and children [7, 26].  
The aim of this study was to develop a novel, reproducible, and sensitive assay using 
fluorescence to quantify heparin-like drugs in human pooled plasma. Consequently, we 
measured the effect of four anticoagulants, UFH, enoxaparin, tinzaparin and danaparoid on 
the fluorogenic anti-FXa assay at anticoagulant concentrations of 0-1.6 U/ml. The intra-assay 
variability and sensitivity limit was established for each of these four drugs. In addition we 
investigated the inter-variability of the assay for all drugs, so the assay for UFH was 
compared with the assay for LMWHs and danaparoid. SPSS statistical analysis proved that 
there were significant differences in assay sensitivity between drugs. 
In the study presented here the anti-FXa assay for UFH was statistically differentiated 
at intervals of 0.2 U/ml up to 1 U/ml and showed excellent reproducibility with CVs below 
7%. The anti-FXa assay was also statistically sensitive up to 0.6 U/ml and 0.8 U/ml for 
tinzaparin and enoxaparin, respectively. Assay reproducibility for both LMWHs was 
excellent with CVs of 0.5-7%. The anti-FXa:anti-FIIa ratios for enoxaparin and tinzaparin are 
2.7:1 and 1.9:1, both exerting a larger inhibitory effect on FXa than thrombin. As has already 
been stated, LMWHs have less of an effect on ACT and APTT than UFH [6], supporting the 
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theory that prolongation of these tests is dependent upon inhibition of thrombin rather than 
FXa, highlighting the need for an anti-FXa activity test. The use of a single calibration curve 
for monitoring LMWHs in children has also been suggested [27]. Strong linearity was 
observed for tinzaparin and enoxaparin calibration curves, with a slight bias towards lower 
anti-FXa activity with tinzaparin. However, the difference was not significant. With the 
present fluorogenic anti-FXa assay, the reaction rates for enoxaparin were marginally higher 
than for tinzaparin, but the differences were not statistically significant as previously reported 
in the literature [27]. 
The use of a point of care chromogenic anti-FXa assay for monitoring enoxaparin in 
patients who have undergone percutaneous coronary intervention (PCI) has been described 
[28]. The chromogenic ENOX assay described can detect anti-FXa levels of 0.63-1.34 U/ml. 
However, at lower ranges of anti-FXa activity, the sensitivity of the assay decreases. An 
analytical range of 0.5-1 U/ml is appropriate for PCI [29, 30] and the fluorogenic assay 
presented here covers this therapeutic range as well as low dose enoxaparin (0.2-0.8 U/ml). 
Danaparoid has the greatest ratio of anti-FXa:anti-FIIa (≥22:1) amongst the 
anticoagulants evaluated and inhibits FXa to a much greater extent than FIIa [4]. The anti-
FXa assay is considered to be the only adequate assay for monitoring danaparoid. In the 
present study, it was established that the fluorogenic anti-FXa assay was capable of detection 
and discrimination of danaparoid up to 1 U/ml where it demonstrated good reproducibility 
with CVs of less than 7%, in addition to good linearity between 0.2 and 1 U/ml. Danaparoid 
cannot be measured using PT, APTT or thrombin clotting time. However, there is a 
requirement to monitor it in patients with elevated levels of creatinine in serum [4]. A study 
compared the APTT, ACT and anti-FXa assays for monitoring danaparoid during 
cardiovascular operations [31]. In spiked samples, APTT and ACT were prolonged in the 
presence of increasing concentrations of danaparoid. However, in patient samples, both 
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assays were insensitive to significant changes in danaparoid levels. The present assay needs 
to undergo evaluation in patient samples before its usefulness can be fully determined.  
In conclusion, a novel fluorogenic anti-FXa assay has been developed which is 
capable of measuring the impact on the anti-FXa activity of therapeutic concentrations of 
several heparin-like anticoagulants, namely UFH, tinzaparin, enoxaparin and danaparoid. The 
assay used 4 nM exogenous FXa and 0.9 µM Pefafluor FXa substrate and was performed in 
commercial human pooled plasmas. This single assay configuration resulted in detection 
ranges of 0 to 1 U/ml for UFH, 0 to 0.6 U/ml tinzaparin, 0 to 0.8 U/ml enoxaparin, and 0 to 1 
U/ml for danaparoid with discrimination between doses of 0.2 U/ml in nearly all cases and 
typical CVs below 7%.  
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